These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 20686276

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G, Vassalle J, Marcus SN, Triadafilopoulos G.
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [Abstract] [Full Text] [Related]

  • 23. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
    [Abstract] [Full Text] [Related]

  • 24. Convenient Method of Measuring Baseline Impedance for Distinguishing Patients with Functional Heartburn from those with Proton Pump Inhibitor-Resistant Endoscopic Negative Reflux Disease.
    Yoshimine T, Funaki Y, Kawamura Y, Tamura Y, Izawa S, Ebi M, Ogasawara N, Murotani K, Sasaki M, Kasugai K.
    Digestion; 2019 Apr; 99(2):157-165. PubMed ID: 30179879
    [Abstract] [Full Text] [Related]

  • 25. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA, Pilmer B, Hunt B, Mody R, Perez MC.
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [Abstract] [Full Text] [Related]

  • 26. Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.
    Tominaga K, Iwakiri R, Fujimoto K, Fujiwara Y, Tanaka M, Shimoyama Y, Umegaki E, Higuchi K, Kusano M, Arakawa T, GERD 4 Study Group.
    J Gastroenterol; 2012 Mar; 47(3):284-92. PubMed ID: 22081052
    [Abstract] [Full Text] [Related]

  • 27. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM, Lesmana E, Fass R.
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [Abstract] [Full Text] [Related]

  • 28. Predictors of proton pump inhibitor failure in non-erosive reflux disease: A study with impedance-pH monitoring and high-resolution manometry.
    Shi Y, Tan N, Zhang N, Xiong L, Peng S, Lin J, Chen M, Xiao Y.
    Neurogastroenterol Motil; 2016 May; 28(5):674-9. PubMed ID: 26768192
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying.
    Futagami S, Iwakiri K, Shindo T, Kawagoe T, Horie A, Shimpuku M, Tanaka Y, Kawami N, Gudis K, Sakamoto C.
    J Gastroenterol; 2010 Apr; 45(4):413-21. PubMed ID: 19997942
    [Abstract] [Full Text] [Related]

  • 31. Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.
    Kohata Y, Fujiwara Y, Yamagami H, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Tominaga K, Arakawa T.
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 1():36-40. PubMed ID: 25827802
    [Abstract] [Full Text] [Related]

  • 32. How to differentiate non-erosive reflux disease from functional heartburn.
    Ke MY.
    J Dig Dis; 2012 Dec; 13(12):605-8. PubMed ID: 23134478
    [Abstract] [Full Text] [Related]

  • 33. A randomized, placebo-controlled, double-blind clinical trial of rikkunshito for patients with non-erosive reflux disease refractory to proton-pump inhibitor: the G-PRIDE study.
    Tominaga K, Kato M, Takeda H, Shimoyama Y, Umegaki E, Iwakiri R, Furuta K, Sakurai K, Odaka T, Kusunoki H, Nagahara A, Iwakiri K, Furuta T, Murakami K, Miwa H, Kinoshita Y, Haruma K, Takahashi S, Watanabe S, Higuchi K, Kusano M, Fujimoto K, Arakawa T, G-PRIDE Study Group.
    J Gastroenterol; 2014 Oct; 49(10):1392-405. PubMed ID: 24535455
    [Abstract] [Full Text] [Related]

  • 34. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease.
    Nojkov B, Rubenstein JH, Adlis SA, Shaw MJ, Saad R, Rai J, Weinman B, Chey WD.
    Aliment Pharmacol Ther; 2008 Mar 15; 27(6):473-82. PubMed ID: 18194508
    [Abstract] [Full Text] [Related]

  • 35. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease.
    Nakamura K, Akiho H, Ochiai T, Motomura Y, Higuchi N, Okamoto R, Matsui N, Yasuda D, Akahoshi K, Kabemura T, Ihara E, Harada N, Ito T, Takayanagi R.
    Hepatogastroenterology; 2010 Mar 15; 57(99-100):497-500. PubMed ID: 20698216
    [Abstract] [Full Text] [Related]

  • 36. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N, Kudo M, Yoshida N, Murakami K, Kato M, Sanuki T, Oshio A, Joh T, Higuchi K, Haruma K, Nakada K.
    J Gastroenterol; 2015 Dec 15; 50(12):1173-83. PubMed ID: 25851931
    [Abstract] [Full Text] [Related]

  • 37. The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder.
    Izawa S, Funaki Y, Iida A, Tokudome K, Tamura Y, Ogasawara N, Sasaki M, Kasugai K.
    Digestion; 2014 Dec 15; 89(1):61-7. PubMed ID: 24458115
    [Abstract] [Full Text] [Related]

  • 38. A single-center retrospective study on epidemiological and Traditional Chinese Medicine syndrome characteristics of 21010 patients with reflux/heartburn symptoms.
    Yanping T, Peicai LI, Xi L, Lei L, Yanxia G, Xiaodong W, Lina L, Li Y.
    J Tradit Chin Med; 2023 Jun 15; 43(3):574-581. PubMed ID: 37147760
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME.
    Cochrane Database Syst Rev; 2010 Nov 10; (11):CD002095. PubMed ID: 21069670
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.